Detalhe da pesquisa
1.
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial.
Cancer
; 126(6): 1175-1182, 2020 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31851385
2.
Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer.
Acta Oncol
; 59(1): 75-81, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31583943
3.
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
Eur J Cancer
; 181: 92-101, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36641898
4.
Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33).
Support Care Cancer
; 19(11): 1789-95, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20953803
5.
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.
Lancet
; 373(9674): 1532-42, 2009 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-19410717
6.
Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial.
ESMO Open
; 5(6): e000979, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33154022
7.
Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.
Cochrane Database Syst Rev
; (3): CD007303, 2009 Jul 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-19588423
8.
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020.
Breast Care (Basel)
; 15(3): 294-309, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32774225
9.
Is symptom-oriented follow-up still up to date?
Breast Care (Basel)
; 8(5): 336-40, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24415986
10.
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial.
J Natl Cancer Inst
; 105(14): 1018-26, 2013 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-23860204
11.
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.
J Clin Oncol
; 28(17): 2874-80, 2010 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-20458045
12.
Response.
J Natl Cancer Inst
; 106(3): djt452, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24586093
13.
Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer).
Breast Care (Basel)
; 4(2): 109-116, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-21049070
14.
Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival.
Cancer
; 104(11): 2417-29, 2005 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16270321